IL227847A0 - Antibody diagnostic test - Google Patents
Antibody diagnostic testInfo
- Publication number
- IL227847A0 IL227847A0 IL227847A IL22784713A IL227847A0 IL 227847 A0 IL227847 A0 IL 227847A0 IL 227847 A IL227847 A IL 227847A IL 22784713 A IL22784713 A IL 22784713A IL 227847 A0 IL227847 A0 IL 227847A0
- Authority
- IL
- Israel
- Prior art keywords
- antibody assay
- diagnostic antibody
- diagnostic
- assay
- antibody
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161453449P | 2011-03-16 | 2011-03-16 | |
| PCT/EP2012/054629 WO2012123562A1 (en) | 2011-03-16 | 2012-03-16 | Diagnostic antibody assay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL227847A0 true IL227847A0 (en) | 2013-09-30 |
Family
ID=45833428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL227847A IL227847A0 (en) | 2011-03-16 | 2013-08-07 | Antibody diagnostic test |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8809508B2 (enExample) |
| EP (1) | EP2686346B1 (enExample) |
| JP (1) | JP6220675B2 (enExample) |
| KR (1) | KR102020072B1 (enExample) |
| CN (1) | CN103459421B (enExample) |
| AU (1) | AU2012228236B2 (enExample) |
| BR (1) | BR112013023211B1 (enExample) |
| CA (1) | CA2828433C (enExample) |
| DK (1) | DK2686346T3 (enExample) |
| EA (1) | EA032054B1 (enExample) |
| IL (1) | IL227847A0 (enExample) |
| MX (1) | MX343873B (enExample) |
| SG (1) | SG192805A1 (enExample) |
| WO (1) | WO2012123562A1 (enExample) |
| ZA (1) | ZA201305946B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210091830A (ko) | 2013-03-15 | 2021-07-22 | 비보리온 테라퓨틱스 아게 | 신규한 억제제 |
| US20170363645A1 (en) | 2014-12-19 | 2017-12-21 | Probiodrug Ag | Novel Method for the Detection of pGlu-Abeta Peptides |
| US10494425B2 (en) * | 2015-02-24 | 2019-12-03 | Rpeptide, Llc | Anti-amyloid-beta antibodies |
| NZ739181A (en) * | 2015-07-16 | 2023-05-26 | Vivoryon Therapeutics N V | Anti-pyroglutamated amyloid beta humanized antibodies |
| GB201910697D0 (en) * | 2019-07-26 | 2019-09-11 | Binding Site Group Ltd | Lonisation control |
| CA3151959A1 (en) * | 2019-10-01 | 2021-04-08 | James Ronald Peyser | Determination of protein concentration in a fluid |
| KR102790945B1 (ko) * | 2022-09-23 | 2025-04-04 | 경성대학교 산학협력단 | 베타-아밀로이드 42를 이용한 치매 진단 방법 및 이를 이용한 치매 진단 키트 |
| CN121253823A (zh) * | 2025-10-10 | 2026-01-02 | 山东九嘉生物科技有限公司 | 一种用于检测胃蛋白酶原ⅰ的化学发光试剂盒及其制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| EP1237930B1 (en) * | 1999-12-08 | 2006-11-08 | Intellect Neurosciences, Inc. | Chimeric amyloid beta peptides |
| US7117096B2 (en) * | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| WO2004013172A2 (en) | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| WO2004029629A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| WO2005075436A2 (en) | 2004-02-05 | 2005-08-18 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| ES2259270B1 (es) | 2005-03-09 | 2007-11-01 | Consejo Superior De Investigaciones Cientificas | Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal. |
| WO2008002893A2 (en) | 2006-06-29 | 2008-01-03 | Centocor, Inc. | Anti-amyloid antibodies, compositions, methods and uses |
| ES2468546T3 (es) | 2006-11-09 | 2014-06-16 | Probiodrug Ag | Nuevos inhibidores de glutaminil ciclasa |
| JP5599614B2 (ja) | 2006-11-09 | 2014-10-01 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| WO2008110523A1 (en) | 2007-03-09 | 2008-09-18 | Probiodrug Ag | Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase |
| ES2468551T3 (es) | 2007-04-18 | 2014-06-16 | Probiodrug Ag | Derivados de nitrovinil-diamina como inhibidores de la glutaminil ciclasa |
| JP5675343B2 (ja) | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としての尿素誘導体 |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| JP5675341B2 (ja) | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオキソキナゾリノン誘導体 |
| EP2160380B1 (en) | 2007-04-18 | 2014-04-02 | Probiodrug AG | Cyano-guanidine derivatives as glutaminyl cyclase inhibitors |
| JP5676249B2 (ja) | 2007-04-20 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体 |
| JP2011500059A (ja) * | 2007-10-15 | 2011-01-06 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ヒト抗アミロイド抗体、組成物、方法及び使用 |
| AT506820B1 (de) * | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
| KR101706789B1 (ko) * | 2008-07-21 | 2017-02-14 | 프로비오드룩 아게 | 진단용 항체 검사법 |
| WO2010128139A1 (en) * | 2009-05-08 | 2010-11-11 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment |
| SI2448968T1 (sl) * | 2009-06-29 | 2021-07-30 | Bioarctic Ab | Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta |
-
2012
- 2012-03-16 CN CN201280013607.2A patent/CN103459421B/zh not_active Expired - Fee Related
- 2012-03-16 EP EP12708855.7A patent/EP2686346B1/en active Active
- 2012-03-16 KR KR1020137023118A patent/KR102020072B1/ko not_active Expired - Fee Related
- 2012-03-16 MX MX2013010571A patent/MX343873B/es active IP Right Grant
- 2012-03-16 WO PCT/EP2012/054629 patent/WO2012123562A1/en not_active Ceased
- 2012-03-16 JP JP2013558453A patent/JP6220675B2/ja not_active Expired - Fee Related
- 2012-03-16 SG SG2013062286A patent/SG192805A1/en unknown
- 2012-03-16 DK DK12708855.7T patent/DK2686346T3/en active
- 2012-03-16 US US13/422,583 patent/US8809508B2/en active Active
- 2012-03-16 BR BR112013023211-0A patent/BR112013023211B1/pt not_active IP Right Cessation
- 2012-03-16 AU AU2012228236A patent/AU2012228236B2/en not_active Ceased
- 2012-03-16 EA EA201301029A patent/EA032054B1/ru not_active IP Right Cessation
- 2012-03-16 CA CA2828433A patent/CA2828433C/en active Active
-
2013
- 2013-08-07 ZA ZA2013/05946A patent/ZA201305946B/en unknown
- 2013-08-07 IL IL227847A patent/IL227847A0/en active IP Right Grant
-
2014
- 2014-05-19 US US14/280,919 patent/US9657089B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NZ614217A (en) | 2015-12-24 |
| EA201301029A1 (ru) | 2014-05-30 |
| BR112013023211A2 (pt) | 2016-11-22 |
| US8809508B2 (en) | 2014-08-19 |
| JP6220675B2 (ja) | 2017-11-01 |
| KR20140006019A (ko) | 2014-01-15 |
| ZA201305946B (en) | 2014-10-29 |
| MX2013010571A (es) | 2013-12-02 |
| WO2012123562A1 (en) | 2012-09-20 |
| CN103459421A (zh) | 2013-12-18 |
| EP2686346B1 (en) | 2016-12-14 |
| BR112013023211B1 (pt) | 2022-11-08 |
| CA2828433A1 (en) | 2012-09-20 |
| DK2686346T3 (en) | 2017-03-27 |
| US20140255414A1 (en) | 2014-09-11 |
| EP2686346A1 (en) | 2014-01-22 |
| US20120237529A1 (en) | 2012-09-20 |
| SG192805A1 (en) | 2013-09-30 |
| JP2014509860A (ja) | 2014-04-24 |
| MX343873B (es) | 2016-11-25 |
| CA2828433C (en) | 2020-08-04 |
| AU2012228236B2 (en) | 2016-10-27 |
| KR102020072B1 (ko) | 2019-11-04 |
| CN103459421B (zh) | 2017-07-14 |
| AU2012228236A1 (en) | 2013-10-03 |
| US9657089B2 (en) | 2017-05-23 |
| EA032054B1 (ru) | 2019-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259826A (en) | Anti-alphabetatisiar antibody | |
| ZA201307983B (en) | Anti-b7-h3 antibody | |
| GB201103955D0 (en) | Antibodies | |
| GB201112056D0 (en) | Antibodies | |
| HUE040213T2 (hu) | Anti-TIM antitest | |
| LT3342786T (lt) | Anti-dll3 antikūnai | |
| PL3653645T3 (pl) | Przeciwciało monoklonalne przeciwko IL-31 | |
| ZA201305946B (en) | Diagnostic antibody assay | |
| TWI563004B (en) | Anti-hxcr1 antibody | |
| GB201007075D0 (en) | Diagnostic reagents | |
| PL2729809T3 (pl) | Test oznaczający | |
| GB201106615D0 (en) | Assay | |
| EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
| GB201102659D0 (en) | Assay | |
| GB201012072D0 (en) | Diagnostic reagents | |
| GB201121265D0 (en) | Assay | |
| GB201113101D0 (en) | Assay | |
| GB201104402D0 (en) | Diagnostic antibody assay | |
| GB201007957D0 (en) | Antibody | |
| GB201111608D0 (en) | Assay | |
| GB201117309D0 (en) | Assay | |
| GB201107431D0 (en) | Assay | |
| GB201121573D0 (en) | Assay | |
| GB201114404D0 (en) | Assay | |
| GB201111698D0 (en) | Assay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |